Do you use elacestrant for all patients with metastatic ER+, HER2-, ESR1 mutated breast cancer regardless of duration of response to prior ET+CDK4/6i?  

Use elacestrant on all patients with ESR1 mutation regardless of length of response 

EMERALD study enrolled patients with ER-positive/HER2-negative advanced breast cancer who had one or two lines of endocrine therapy, required pretreatment with a CDK4/6i, and ≤ 1 chemotherapy in all comers (with or without detectable ESR1 mutations). ESR1 mutation was detected in less than half (...